A life-saving solution for treatment of acute respiratory viral infections
Explore the potential of arvidal, an innovative antiviral therapy. With its peptide-based composition, arvidal offers a safe and effective solution against a wide range of viral infections. This broad-spectrum drug not only combats viruses directly but also enhances your immune response, ensuring a comprehensive defense mechanism.
A solution for both prevention and treatment of respiratory viral infections;
Safely boosts local immunity, essential during epidemic seasons;
Suppresses the hypersecretion of pro-inflammatory cytokines;
Decreases the cough intensity without affecting the respiratory center;
Easy to use, with minimal side effects for patient comfort.
About ARVIDAL
According to the World Health Organization (WHO), our world is home to approximately 300 different respiratory viral pathogens, making acute respiratory viral infections (ARVI) the most prevalent infectious diseases today. These infections, led by the notorious coronaviruses, and recurrent strains of influenza A and B, along with seasonal coronaviruses, bocaviruses, metapneumoviruses, and rhinoviruses, pose a significant and ongoing challenge to global health. Particularly concerning is the high rate of co-infections, which complicates treatment and prevention strategies. This evolving landscape of respiratory viruses demands constant vigilance and innovative healthcare solutions to protect communities worldwide.
ARVIDAL, a promising antiviral agent, has demonstrated significant efficacy both in vitro (within cell cultures infected by viruses) and in vivo (using animal models of viral infections, including influenza and adenoviral respiratory infections). These studies reveal ARVIDAL's dual-action mechanism: a direct antiviral effect paired with the stimulation of both local and systemic immunological defenses. Uniquely, ARVIDAL's peptide-based composition ensures an optimal physiological response, seamlessly integrating into the body's natural processes. Its breakdown into simple amino acids, which are fundamental to protein synthesis, underscores its harmonious interaction with the body's biochemistry. Building on this robust foundation of preclinical success, ARVIDAL has now secured authorization to enter phase 3 clinical trials, marking a significant milestone in its journey towards potential widespread medical use.
Mechanism of Action
Agonist of µ-opioid receptors.
Relieves acute lung injury and prevents pneumonia
Suppresses hypersecretion of pro-inflamatory cytokines (IL-1, IL-6 and TNF-α)
Stimulates the production of endogenous interferons
Regulates the activity of the phagocytic component of innate immunity (macrophages and neutrophols), as well as the activity of lymphocytes - natural killers
ARVIDAL ([D-Ala2, Leu5]-enkephalyl-Arg, dalargin) possesses a unique mechanism of action: it has both a direct antiviral effect and a pronounced ability to regulate the factors of local and systemic immunological defense.
ARVIDAL:
• Effectively reduces the excessive production of key inflammatory agents (IL-1, IL-6, and TNF-α), helping to control severe inflammation and mitigate the effects of cytokine storm and associated respiratory distress. stimulates phagocytosis of neutrophils and macrophages, along with the activity of lymphocytes - natural killers;
• Promotes the early production of the body's own interferons, key players in the immune response against the initial stages of infection;
• Activates tissue regeneration due to reparative and cytoprotective properties, membrane-stabilizing and antioxidant effects;
• Safely reduces cough intensity, providing relief without impacting the central respiratory system.
ARVIDAL:
• Effectively reduces the excessive production of key inflammatory agents (IL-1, IL-6, and TNF-α), helping to control severe inflammation and mitigate the effects of cytokine storm and associated respiratory distress. stimulates phagocytosis of neutrophils and macrophages, along with the activity of lymphocytes - natural killers;
• Promotes the early production of the body's own interferons, key players in the immune response against the initial stages of infection;
• Activates tissue regeneration due to reparative and cytoprotective properties, membrane-stabilizing and antioxidant effects;
• Safely reduces cough intensity, providing relief without impacting the central respiratory system.
Structure-based properties.
Possible therapeutical areas
Conditions for treatment with ARVIDAL
Skin wounds and burns
Users can apply this peptide-based burn treatment and wound healing spray to the affected area. It acts on various mechanisms that contribute to the healing of wounds of various etiologies. It has shown extreme efficacy in providing pain relief, reducing inflammation, shielding skin lesions from microorganisms, stimulating skin cell metabolism, and ensuring scar-free wound healing.
Ulcer
[D-Ala2, Leu5]-enkephalyn-Arg in form of lyophilisate for intravenous and intramuscular injection solution, 1 mg, is used to treat peptic ulcer of the stomach and duodenum and acute pancreatitis for over 30 years.
Protection of the oral mucosa
For individuals aged 60 and older, safeguarding the mucosa becomes increasingly crucial due to natural atrophic changes in the body's mucous membranes, including those in the nasopharynx and throat. These changes can lead to slower blood circulation in the mucous membranes, thinning of the epithelium and a reduction in the number of protective microvilli. ARVIDAL® offers a unique and safe solution to enhance local immunity.
arvidal: Your Ally in the Battle Against Pneumonia and Its complications
Can be used for the complex treatment of pneumonia associated with COVID-19 or influenza. It plays a crucial role in averting the cytokine storm, a serious complication of these infections. Pneumonia can lead to severe lung damage, particularly pulmonary fibrosis, where lung tissue becomes irreversibly scarred, impairing lung function. Addressing this, Arvidal’s regenerative properties are pivotal. They significantly reduce the risk of pathological changes in the lungs, including the development of fibrotic lesions, offering a proactive approach to prevent long-term lung damage and promote tissue healing.
arvidal: Comprehensive Protection Against a Spectrum of Viral Threats
arvidal stands as a powerful ally in both the prevention and treatment of a wide range of viral infections. Its protective immunomodulatory activity makes it particularly effective against a range of viruses, including seasonal and pandemic influenza A and B, various types of coronaviruses (including alpha-, beta-, gamma- and deltacoronaviruses, as well as SARA-CoV and MERS coronaviruses), adenoviruses, respiratory syncytial viruses, parainfluenza, rhinoviruses, human metapneumoviruses, bocaviruses, and even infections of combined etiology.
Dosing
Final dosage form
arvidal is available in multiple, user-friendly formats to meet diverse needs and preferences. Available as an antiviral nasal spray, it's perfect for easy and effective irrigation of the mouth and nose, providing direct protection where it's most needed. Additionally, we provide a solution for inhalation, ideally administered through devices like nebulizers, ensuring deep lung penetration for comprehensive respiratory defense.
Spray: Your First Line of Defense in Early Infection Stages
Effortlessly easy to use and effective especially during the early phase of infection. Protects the upper airways – the primary entry points for the viruses.
Mode of administration
The spray is used in each nasal passage with a deep inhalation and target the back of the throat five times daily, maintaining a minimum interval of two hours between applications, for up to seven days. To ensure optimal effectiveness, drinking or eating immediately after treatment for about 10 minutes should be avoided.
Preventive Measures with arvidal
Ideal for those at heightened risk, ARVIDAL® can be administered to prevent ARVI in healthy people, especially those at risk. In order to establish a protective "barrier" against infection. Regular irrigation of the nasopharynx with our easy-to-use spray helps prevent the invasion of pathogens into the throat, trachea, and bronchi.
Inhalation Solution: A Robust Defense in the Later Stages of Infection
Our inhalation solution is specifically designed to be highly effective in the later phases of infection, targeting and protecting the lower airways. It plays a crucial role in preventing serious complications like pneumonia and pulmonary fibrosis.
Mode of administration
For inhalation, it is preferable to use a compressor-type nebulizer with a particle size of 0.5-3 micrometers. Inhalation is carried out until the solution is completely exhausted, taking deep, calm breaths. To maximize the effectiveness of the treatment, avoid eating or drinking for approximately 10 minutes after inhalation. For comprehensive care, perform inhalations four times a day, maintaining at least a four-hour interval between each session, over a period of seven days.
ARVIDAL was patented in USA, China, Japan, the European Union, the Eurasian Commonwealth, Russia and Nigeria. Patent applications for the national phase have been filed in the Canada, Singapore, India, Indonesia, Vietnam, Korea, ARIPO countries. Trademark applications are filed in 46 countries.
